For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor ...

The use of anticoagulants offers significant benefits. They are indicated for various uses depending on the specific anticoagulant used, including: These medications protect individuals at high ...

The study analyzed blood samples of turkey vultures in southern California. Scientists make disturbing new discovery after ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets.

Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

It further said that the single-dose ampules are both bioequivalent and therapeutically equivalent to the reference listed ...